Myelodysplastic syndromes
23332- A randomized, double-blind, placebo-controlled, multicenter phase 2 study of AK117/placebo in combination with azacitidine in patients with newly diagnosed higher-risk myelodysplastic syndrome (AK117-205)
STAR TRIAL = 2 WEEKS TO OPEN
- Phase – II
- Stage(s) – Newly Diagnosed HR-MDS
- Line of Therapy – 1st
- Investigational Drug – AK117
- Drug Class – CD47
- Mechanism of Action – AK117 blocks the macrophage inhibitory immune checkpoint cluster of differentiation CD47